AGameChangerinKRASG12DCancerTreatment:VerastemOncology

Sometimes you just have to feel like cheering.

That is exactly what happened at ASCO this year when the RVMD daraxonrasib data dropped in pancreatic cancer. The room erupted. Scientists and clinicians who spend their careers in one of oncology’s most unforgiving tumor types stood up and applauded. That moment matters, because it tells you the field knows when something real is happening.

We felt that same electricity listening to the Verastem conference call yesterday. The enthusiasm of the presenting executives was infectious.They know they have a game changer. That quality of conviction is something you learn to recognize when you do this long enough, and it was all over that call.
We are talking about an oral drug which is not toxic and has very tolerable side effects. The fact that they are in advanced discussions with other biopharmas to combine VS7375 with known entities is telling in itself. 

Here is what they have. VS-7375 is an oral KRAS G12D ON/OFF inhibitor targeting one of the most notoriously undruggable mutations in cancer, present across pancreatic, colorectal, and lung tumors. Dose escalation has progressed from 400 mg through 900 mg QD without dose-limiting toxicities, with the study now evaluating a 1200 mg QD monotherapy dose alongside combination cohorts. No meaningful liver toxicity. No significant hematologic issues. GI side effects tracking lower than competitor data, with no drug-related neutropenia greater than Grade 2. For a drug chasing one of the hardest targets in oncology, that safety fingerprint is remarkable.That is a fundamental differentiator.

The RAMP 205 combination arm, pairing avutometinib and defactinib with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer, showed an 86% overall survival rate at 6 months, 68% progression-free survival at 6 months, and a confirmed objective response rate of 52% across 29 patients. In pancreatic cancer, those numbers do not come easily.

The fact that Verastem is in advanced discussions with other biopharma companies to combine VS-7375 with established agents is telling in itself. You do not attract serious combination partners unless the underlying molecule has earned genuine scientific respect. Three Phase 2 registration-directed trials are now running across metastatic PDAC, 2L/3L NSCLC, and metastatic CRC and the FDA has granted Fast Track Designation for both pancreatic and NSCLC indications. Three separate accelerated approval pathways across three of the deadliest solid tumor types. That is not a speculative pipeline. That is a serious development machine.

We do not know what the market is thinking right now. But we do. We are all in on $VSTM.